PA
TMDX icon

PharVision Advisers’s Transmedics TMDX Stock Holding History

PharVision Advisers’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,841
Closed -$431K – 998
2025
Q3 		$431K Buy
3,841
+1,871
+95% +$219K 0.24% 53
2025
Q2 		$264K Buy
+1,970
New +$216K 0.38% 113

Other funds holding TMDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

PharVision Advisers's TMDX Position: Q4 2025 in Review

PharVision Advisers sold out of Transmedics (TMDX) in Q4 2025, closing a stake of 3,841 shares — an estimated $431K sold.

PharVision Advisers first reported a position in TMDX in Q2 2025 and held it in 2 quarters. The position peaked at $431K in Q3 2025. 428 funds tracked by Wall St. Rank hold TMDX as of Q4 2025.

  • PharVision Advisers reported no remaining Transmedics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 3,841 Transmedics shares in Q4 2025, an estimated $431K.
  • PharVision Advisers first reported a position in Transmedics in Q2 2025 and held it in 2 quarters.
  • PharVision Advisers's Transmedics position peaked at $431K in Q3 2025.
  • 428 funds tracked by Wall St. Rank held Transmedics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.